Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
NERV 
Minerva Neurosciences Inc (NERV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: NERV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.29% | Avg. Invested days 38 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.92M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta -0.42 | 52 Weeks Range 1.15 - 6.41 | Updated Date 12/7/2025 |
52 Weeks Range 1.15 - 6.41 | Updated Date 12/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.82% | Return on Equity (TTM) -675.09% |
Valuation
Trailing PE - | Forward PE 11.21 | Enterprise Value 15154080 | Price to Sales(TTM) 1.87 |
Enterprise Value 15154080 | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 2.6 | Shares Outstanding 6993406 | Shares Floating 5437023 |
Shares Outstanding 6993406 | Shares Floating 5437023 | ||
Percent Insiders 22.25 | Percent Institutions 28.26 |
Upturn AI SWOT
Minerva Neurosciences Inc
Company Overview
History and Background
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat central nervous system (CNS) diseases. Founded in 2007, it has focused on developing compounds to address unmet medical needs in psychiatry.
Core Business Areas
- Clinical Development: Focuses on advancing its product pipeline through clinical trials and regulatory submissions.
- Research and Development: Engages in research to discover and develop new therapies for CNS disorders.
Leadership and Structure
The leadership team consists of experienced professionals in drug development and commercialization. The organizational structure is typical of a clinical-stage biotech company, with emphasis on research, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Rolipram: Rolipram is being developed for the treatment of major depressive disorder (MDD). Rolipram does not currently have FDA approval. Key competitors would include SSRIs, SNRIs, and other atypical antidepressants from companies like Eli Lilly (LLY), Pfizer (PFE), and GlaxoSmithKline (GSK).
Market Dynamics
Industry Overview
The CNS therapeutics market is characterized by high unmet needs and significant growth potential, driven by an aging population and increasing prevalence of mental health disorders.
Positioning
Minerva Neurosciences focuses on developing novel therapies for specific CNS disorders. Its competitive advantage lies in its novel compounds and targeted approach.
Total Addressable Market (TAM)
The TAM for MDD therapeutics is estimated to be in the billions of dollars annually. Minerva's Rolipram would be competing in this large market if approved.
Upturn SWOT Analysis
Strengths
- Novel compounds in development
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Reliance on single product candidate (Rolipram)
- Limited financial resources
- Regulatory uncertainty
- History of clinical trial setbacks
Opportunities
- Positive clinical trial results for Rolipram
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through in-licensing or acquisition
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- PFE
- GSK
- ALKS
Competitive Landscape
Minerva Neurosciences competes with established pharmaceutical companies that have greater resources and experience. Its competitive advantage lies in its novel compounds and targeted approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's clinical-stage status. Growth is primarily reflected in the expansion of its research and development programs.
Future Projections: Future growth is highly dependent on the successful development and commercialization of Rolipram.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Rolipram and efforts to secure regulatory approval.
Summary
Minerva Neurosciences is a high-risk, high-reward clinical-stage biopharmaceutical company. The company's future is heavily reliant on the successful development and commercialization of Rolipram. While it possesses novel compounds and a targeted approach, it faces significant challenges in terms of funding, regulatory hurdles, and competition from larger pharmaceutical companies. Investors should be aware of the inherent risks associated with investing in a company at this stage of development.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Minerva Neurosciences Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2014-07-01 | Executive Chairman & CEO Dr. Remy Luthringer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | |
Full time employees 8 | |||
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.